Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iHSC is an induced pluripotent stem cell (iPSC)-derived hematopoietic stem cell therapy being developed by All Life Biotechnology. The therapy utilizes iPSC technology to generate a standardized and potentially unlimited supply of functional hematopoietic stem cells (HSCs) for transplantation. This approach is designed to overcome the limitations of traditional HSC transplants, such as donor scarcity and the need for HLA matching. iHSC is currently in Phase 1/2 clinical development for the treatment of genetic blood disorders, including Thalassemia and Fabry Disease, where it aims to reconstitute healthy hematopoietic lineages. It is also being investigated for use in blood cancers and as a source for general hematopoietic stem cell transplantation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iHSC.